Healthcare
electroCore, Inc.(ECOR)
Live Price
Offline$8.43
-3.11% today
1Y Change
+40.19%
Window
Jun 26, 2025 โ Jun 24, 2026
- Market Cap
- $60.00M
- Revenue Growth
- +27.2%
- EPS Growth
- -3.8%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 26, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
electroCore, Inc. (ECOR) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $8.43 and up 40.2% across the available one-year price window (Jun 26, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +27.2%, EPS growth of -3.8%, a dividend yield of 0.0%. What stands out right now is revenue +27.2%, EPS -3.8%, free cash flow -18.8% with operating margin -41.1% and ROIC -171.0%. Valuation is more restrained than many high-expectation growth names at price/sales 1.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ECOR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+27.2% vs +7.6% peer median
Operating Margin
Below sector median
-41.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +27.2% and EPS is at -3.8%, with operating margin around -41.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -5.9% | -5.1% | +49.2% |
2026 Mar 19, 2026 | +2.9% | -4.7% | -8.2% | -0.8% |
2025 Nov 5, 2025 | -11.1% | +23.2% | +27.8% | +4.4% |
Benchmark Edge
ECOR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ECOR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ECOR Max Drawdown
-45.99%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ECOR and SPY.
Company Overview
electroCore, Inc.
NASDAQ Capital Market
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
- Leadership
- Thomas J. Errico
- IPO Date
- Jun 22, 2018
- Employees
- 73
- Street Address
- 200 Forge Way
- Mailing
- Rockaway, NJ, 07866
- Region
- Rockaway, NJ, US
- Reporting Currency
- USD
- Investor Line
- 973 290 0097
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.8
- Price/Book
- โ
Growth
- Revenue
- +27.2%
- EPS
- -3.8%
- Free Cash Flow
- -18.8%
Profitability
- Gross Margin
- 86.8%
- Operating Margin
- -41.1%
- Net Margin
- -43.6%
- ROE
- -2072.1%
- ROIC
- -171.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.